| scholarly article | Q13442814 |
| P2093 | author name string | Martin Walker | |
| María-Gloria Basáñez | |||
| Hugo C Turner | |||
| Donald A P Bundy | |||
| Sébastien D S Pion | |||
| Deborah A McFarland | |||
| P2860 | cites work | Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal | Q21144535 |
| Generalized cost-effectiveness analysis for national-level priority-setting in the health sector | Q24807372 | ||
| Productivity Loss Related to Neglected Tropical Diseases Eligible for Preventive Chemotherapy: A Systematic Literature Review | Q26764931 | ||
| Cost and cost-effectiveness of soil-transmitted helminth treatment programmes: systematic review and research needs | Q26825338 | ||
| Cost-benefits of onchocerciasis control | Q46894011 | ||
| Farm land size and onchocerciasis status of peasant farmers in south-western Nigeria | Q47310802 | ||
| Measuring global health: motivation and evolution of the Global Burden of Disease Study | Q47320459 | ||
| Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs | Q47553077 | ||
| Economic evaluations of mass drug administration: The importance of economies of scale and scope | Q47612597 | ||
| Mectizan delivery systems and cost recovery in the Central African Republic | Q50109957 | ||
| Disability weights in the Global Burden of Disease 2010: unclear meaning and overstatement of international agreement | Q50190565 | ||
| The onchocerciasis focus at Kinsuka/Kinshasa (Republic of Zaire) in 1985. I. Entomological aspect. | Q50552388 | ||
| Community financing of local ivermectin distribution in Nigeria: potential payment and cost-recovery outlook. | Q50654406 | ||
| Willingness to pay for community-based ivermectin distribution: a study of three onchocerciasis-endemic communities in Nigeria. | Q50658278 | ||
| Alternative treatment strategies to accelerate the elimination of onchocerciasis. | Q51409120 | ||
| Control of onchocerciasis today: status and challenges. | Q52593136 | ||
| Relationships between mortality, visual acuity and microfilarial load in the area of the Onchocerciasis Control Programme. | Q53927651 | ||
| Discounting in Economic Evaluations. | Q55347831 | ||
| The economics of blindness prevention in upper volta under the Onchocerciasis Control Program | Q56550222 | ||
| Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement | Q56880246 | ||
| Community-directed vector control to supplement mass drug distribution for onchocerciasis elimination in the Madi mid-North focus of Northern Uganda | Q56910124 | ||
| Disability weights for vision disorders in Global Burden of Disease study – Authors' reply | Q57253133 | ||
| Valuing the Unpaid Contribution of Community Health Volunteers to Mass Drug Administration Programs | Q58321649 | ||
| Burden of onchocerciasis-associated epilepsy: first estimates and research priorities | Q58717255 | ||
| How can onchocerciasis elimination in Africa be accelerated? Modeling the impact of increased ivermectin treatment frequency and complementary vector control | Q59485071 | ||
| Prevalence, intensity and ocular manifestations of Onchocerca volvulus infection in Dimbelenge, Zaire | Q64361130 | ||
| Economic burden of blindness in India | Q74621249 | ||
| Onchocerciasis: the beginning of the end | Q87851822 | ||
| Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies | Q90042723 | ||
| The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study | Q91882215 | ||
| Progress towards eliminating onchocerciasis in the WHO Region of the Americas: verification of elimination of transmission in Guatemala | Q95557189 | ||
| Can Economic Analysis Contribute to Disease Elimination and Eradication? A Systematic Review | Q27012936 | ||
| Research for new drugs for elimination of onchocerciasis in Africa | Q28066402 | ||
| Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 | Q28083357 | ||
| HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health | Q28209412 | ||
| Socioeconomic aspects of neglected tropical diseases | Q28271639 | ||
| Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases | Q28273898 | ||
| The Mectizan Donation Program: 20 years of successful collaboration - a retrospective | Q28291428 | ||
| National mass drug administration costs for lymphatic filariasis elimination | Q28469337 | ||
| African Programme For Onchocerciasis Control 1995-2015: model-estimated health impact and cost | Q28485398 | ||
| The cost of annual versus biannual community-directed treatment of onchocerciasis with ivermectin: Ghana as a case study | Q28533627 | ||
| Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa | Q28546065 | ||
| The Contributions of Onchocerciasis Control and Elimination Programs toward the Achievement of the Millennium Development Goals | Q28547416 | ||
| Financial and Economic Costs of the Elimination and Eradication of Onchocerciasis (River Blindness) in Africa | Q28547910 | ||
| African Program for Onchocerciasis Control 1995-2010: Impact of Annual Ivermectin Mass Treatment on Off-Target Infectious Diseases | Q28548420 | ||
| Exploring Consumer Perceptions and Economic Burden of Onchocerciasis on Households in Enugu State, South-East Nigeria | Q28551187 | ||
| Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness? | Q28602538 | ||
| Projected benefits from integrating NTD programs in sub-Saharan Africa | Q29398511 | ||
| The cross-cutting contribution of the end of neglected tropical diseases to the sustainable development goals | Q30061753 | ||
| The Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical Diseases | Q30378480 | ||
| Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. | Q30485861 | ||
| The potential impact of moxidectin on onchocerciasis elimination in Africa: An economic evaluation based on the Phase II clinical trial data | Q30936469 | ||
| Nodding syndrome and epilepsy in onchocerciasis endemic regions: comparing preliminary observations from South Sudan and the Democratic Republic of the Congo with data from Uganda | Q31061763 | ||
| Evolution and patterns of global health financing 1995-2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries | Q31954044 | ||
| The real and the nominal? Making inflationary adjustments to cost and other economic data | Q33180473 | ||
| River blindness: a success story under threat? | Q33258476 | ||
| Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis | Q33603042 | ||
| Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules | Q33606843 | ||
| Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections | Q33681574 | ||
| Modelling the health and economic impacts of the elimination of river blindness (onchocerciasis) in Africa | Q33699144 | ||
| African programme for onchocerciasis control 1995-2015: updated health impact estimates based on new disability weights | Q33716810 | ||
| Economic notes. Discounting | Q33743551 | ||
| Health metrics for helminth infections | Q33748193 | ||
| Cost-effectiveness of triple drug administration (TDA) with praziquantel, ivermectin and albendazole for the prevention of neglected tropical diseases in Nigeria | Q33873632 | ||
| Reaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa | Q34202166 | ||
| Density-dependent mortality of the human host in onchocerciasis: Relationships between microfilarial load and excess mortality | Q34222734 | ||
| Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: proving the feasibility at national scale | Q34422256 | ||
| Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal | Q34431565 | ||
| Case-control studies on the relationship between onchocerciasis and epilepsy: systematic review and meta-analysis | Q34654304 | ||
| The Onchocerciasis Elimination Program for the Americas (OEPA). | Q34811187 | ||
| Thresholds for the cost-effectiveness of interventions: alternative approaches | Q35119997 | ||
| Managing the Fight against Onchocerciasis in Africa: APOC Experience | Q35606749 | ||
| Investing in Onchocerciasis Control: Financial Management of the African Programme for Onchocerciasis Control (APOC). | Q35606953 | ||
| Economic evaluation of Mectizan distribution | Q35743781 | ||
| Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: identifying best practices to roll out programs at national scale | Q35771830 | ||
| Concerted Efforts to Control or Eliminate Neglected Tropical Diseases: How Much Health Will Be Gained? | Q35927181 | ||
| Benchmarking the Cost per Person of Mass Treatment for Selected Neglected Tropical Diseases: An Approach Based on Literature Review and Meta-regression with Web-Based Software Application | Q36213356 | ||
| Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal | Q36303283 | ||
| Socioeconomic consequences of blinding onchocerciasis in west Africa. | Q36794881 | ||
| Potential lost productivity resulting from the global burden of uncorrected refractive error | Q37202048 | ||
| Developing eradication investment cases for onchocerciasis, lymphatic filariasis, and human African trypanosomiasis: rationale and main challenges | Q37288857 | ||
| Visual loss in an onchocerciasis endemic community in Sierra Leone | Q37299674 | ||
| Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research | Q37540358 | ||
| Disability weights in the global burden of disease 2010 study: two steps forward, one step back? | Q37630275 | ||
| The value of productivity: human-capital versus friction-cost method. | Q37649089 | ||
| Human onchocerciasis--an overview of the disease. | Q37944210 | ||
| Productivity costs in economic evaluations: past, present, future. | Q38101894 | ||
| Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: a systematic review | Q38201974 | ||
| Neglected tools for neglected diseases: mathematical models in economic evaluations | Q38279486 | ||
| River Blindness: Mathematical Models for Control and Elimination | Q38809293 | ||
| Indices of onchocerciasis transmission by different members of the Simulium damnosum complex conflict with the paradigm of forest and savanna parasite strains. | Q38867169 | ||
| The African Programme for Onchocerciasis Control: impact on onchocercal skin disease | Q38870400 | ||
| Where would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa | Q38870646 | ||
| Progress towards the elimination of onchocerciasis as a public-health problem in Uganda: opportunities, challenges and the way forward | Q38877998 | ||
| Implementing community-directed treatment with ivermectin for the control of onchocerciasis in Uganda (1997-2000): an evaluation | Q38884435 | ||
| The community-directed, ivermectin-treatment programme for onchocerciasis control in Uganda--an evaluative study (1993-1997). | Q38886167 | ||
| The Onchocerciasis Control Programme in West Africa (OCP). | Q38912503 | ||
| Nodding Syndrome in Onchocerciasis Endemic Areas | Q38950251 | ||
| Genome-wide analysis of ivermectin response by Onchocerca volvulus reveals that genetic drift and soft selective sweeps contribute to loss of drug sensitivity | Q38977668 | ||
| Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis. | Q38984622 | ||
| Cameroon and Chad: cost recovery | Q39025966 | ||
| Point-of-care mobile digital microscopy and deep learning for the detection of soil-transmitted helminths and Schistosoma haematobium. | Q39074123 | ||
| Ranking 93 health interventions for low- and middle-income countries by cost-effectiveness | Q39077555 | ||
| Nodding syndrome: Preventable and treatable | Q39137453 | ||
| A critical re-examination of the economics of blindness prevention under the Onchocerciasis Control Programme | Q39238999 | ||
| Willingness to pay for the maintenance of equity in a local ivermectin distribution scheme in Toro, Northern Nigeria. | Q39325604 | ||
| Doing well while fighting river blindness: the alignment of a corporate drug donation programme with responsibilities to shareholders | Q39559607 | ||
| Profile of eye lesions and vision loss: a cross-sectional study in Lusambo, a forest-savanna area hyperendemic for onchocerciasis in the Democratic Republic of Congo | Q39639940 | ||
| Onchocerciasis in field workers at Baya Farm, Teppi Coffee Plantation Project, southwestern Ethiopia: prevalence and impact on productivity | Q40618904 | ||
| Discounting in health care decision-making: time for a change? | Q41109075 | ||
| Cost-effectiveness of blindness prevention by the Onchocerciasis Control Programme in Upper Volta | Q41436905 | ||
| 40 Years of the APOC Partnership | Q42554496 | ||
| Delivery systems and cost recovery in Mectizan treatment for onchocerciasis. | Q43935182 | ||
| Ocular onchocerciasis and intensity of infection in the community. I. West African savanna. | Q43936575 | ||
| Effects of repeated doses of ivermectin on ocular onchocerciasis: community-based trial in Sierra Leone | Q44002184 | ||
| Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines | Q45352558 | ||
| Disability weights for vision disorders in Global Burden of Disease study. | Q45908187 | ||
| A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa-Endemic Areas | Q46372145 | ||
| Economic impact of onchocerciasis control through the African Programme for Onchocerciasis Control: an overview | Q46562188 | ||
| Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study | Q46597581 | ||
| For as long as necessary: examining 30 years of Merck & Co., Inc.'s focus on achieving elimination of onchocerciasis and lymphatic filariasis | Q46788721 | ||
| APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. African Programme for Onchocerciasis Control | Q46796253 | ||
| Analysis of costs and benefits of the Gambian Eye Care Program | Q46854756 | ||
| Onchocerciasis in an oil palm estate | Q46875015 | ||
| P433 | issue | 7 | |
| P921 | main subject | onchocerciasis | Q1137321 |
| P304 | page(s) | 788-816 | |
| P577 | publication date | 2019-05-09 | |
| P1433 | published in | Tropical Medicine and International Health | Q15765747 |
| P1476 | title | Economic evaluations of onchocerciasis interventions: a systematic review and research needs | |
| P478 | volume | 24 |
Search more.